Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire

Aug.08.2022
Philippines President Defies Public Health, Allows E-Cigarette Bill to Expire
The Philippines' proposed e-cigarette law facing opposition from health officials and advocates for public health.

On his first day in office, Philippine President Marcos vetoed the bill to establish the special ecological zone at the Bura-gan airport city, sending a message that public interest should prevail over commercial profits.


However, the proposed Nicotine and Non-Nicotine Aerosol Products Regulation Act appears to be anything but. The President allowed the act to lapse on July 25th. While the e-cigarette bill would expand its market base and bring more funding to the tobacco industry, it is seen as harmful to health because it would allow individuals as young as 18 to buy, use, and sell e-cigarettes and heated tobacco products, and would lift flavor restrictions on e-cigarette liquids.


The National Health, Food and Drug Administration, Ministry of Education, Ministry of Finance, as well as dozens of medical associations and former health ministers, are strongly lobbying against an electronic cigarette bill. They believe that this puts the country's youth at risk of harmful effects from electronic cigarettes. Former health minister Francisco Duque opposed the claim that electronic cigarettes can help people quit smoking. He said that they typically have the opposite effect as they lead people to engage in more bad habits such as drinking and illegal drug use.


The Philippines is one of the countries with the highest smoking rates among adults and youth around the world. The Global Adult Tobacco Survey in 2015 revealed that nearly 23.8% of Filipino adults used some form of tobacco, with 22.7% of the population being smokers and 18.7% of them being daily smokers.


Approximately 117,000 people die each year in the country due to tobacco-related illnesses such as lung cancer and cardiovascular disease. The cost of treating the four main diseases caused by tobacco use in the Philippines is estimated to be 46.4 billion pesos.


Child rights activists and tobacco control advocates believe that the e-cigarette bill is a "victory for tobacco capital.


The public interest law organization, ImagineLaw, has stated that allowing this bill to become law would be a "betrayal of public health" and a "regrettable development" in light of President Marcos' promise to rebuild the country better.


When the President does not take action after receiving a legislative measure for 30 days, the legislation expires. The previous Congress shelved the e-cigarette bill for five months and on June 24th forwarded a registered copy to Malacañang, just six days before then-President Rodrigo Duterte's term ended.


Health experts and tobacco control advocates are calling for the rejection of the proposed bill, as its provisions conflict with public health goals and international standards, particularly in light of the Supreme Court's ruling in late June upholding the FDA's jurisdiction over tobacco products and reaffirming the country's commitment to the World Health Organization's Framework Convention on Tobacco Control.


Marcos hails from the Ilocos region where tobacco is the main cash crop. Allowing the electronic cigarette bill to expire puts narrow interests ahead of the common good.


Some are calling for the immediate convening of the Legislative-Executive Development Advisory Council (LEDAC) by the President and have pointed out that while the veto power is within the President's rights, its frequent use may strain relations between the executive and legislative branches of government.


In the coming days when meeting with congressional leaders, it should be clear that they will prioritize legislation that serves the public interest, rather than industry profits. The public interest should never be relegated to a secondary position.


Statement:


This article is compiled from third-party information and is intended for industry exchange and learning only.


This article does not represent the viewpoint of 2FIRSTS, and 2FIRSTS cannot confirm the truth or accuracy of the article's content. The compilation of this article is only intended for communication and research within the industry.


Due to limitations in the compiler's ability, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
US ITC Judge Finds Glas Infringed Two JUUL Vape Patents, Recommends Restrictions on Related Imports——Glas Received FDA Marketing Authorization for Four Vape Pods in May 2026; Proposed Restrictions Remain Under Commission Review
A U.S. International Trade Commission (USITC) administrative law judge issued an initial determination on October 20, 2026, finding that certain Glas vaping devices, cartridges and components infringed 12 claims across two patents asserted by JUUL, constituting a violation of Section 337 of the Tariff Act of 1930. The judge recommended a limited exclusion order and a cease and desist order against the Glas respondents. Five months earlier, the FDA authorized four Glas e-cigarette pods, including mango, blueberry and two menthol variants. The patent investigation concerns device and cartridge structures and is separate from FDA premarket review. The proposed import restrictions have not become final, and their product-level scope remains unresolved.
company
Nov.05
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-Founded Nicotine Pouch Retailer GotPouches Shifts to U.S.-Based Operations, Reaching Over 25 States
Swedish-founded online nicotine pouch retailer GotPouches has completed the localization of its U.S. operations under UpNorth Retail LLC, with corporate operations in Franklin, Tennessee, domestic fulfillment from Nashville and U.S.-based customer support. The company says its catalog covers more than 20 nicotine pouch brands and it currently serves customers in more than 25 U.S. states.
Sep.18
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14